This study looks at people with eosinophilic esophagitis (EoE), a condition where a type of white blood cell called eosinophils builds up in the esophagus, making it hard to swallow. Researchers want to understand how a medicine called DUPIXENT® (dupilumab) helps treat EoE as part of regular care. Participants will answer questions about how EoE affects their feelings, symptoms, daily life, and swallowing over time.

Eligibility: To join, you must start using DUPIXENT® for EoE and be able to answer questions. You cannot join if you are allergic to DUPIXENT®, have used it in the past six months, or are part of another treatment study recently.

• The study is observational, meaning no extra treatment is given, just observation.
• Participants must fill out questionnaires about their condition.
• Joining helps improve understanding of EoE but may not directly benefit the participant.